{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0008707\nAge: 66\nGender: Female\nSample ID: P-0008707-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Pancreatic Neuroendocrine Tumor\nSample Type: Metastasis\nTumor Purity: 60.0%\n=============\nDNA Variants:\nDAXX c.1603G>T (p.E535*) - in 59.00% of 235 reads\nMEN1 c.753del (p.I252Lfs*34) - in 60.00% of 302 reads\nCNA Data:\nCDKN2B - Homozygous Deletion\nCDKN2A - Homozygous Deletion\nCDKN2Ap14ARF - Homozygous Deletion\nGNAS - High Level Amplification\nCDKN2Ap16INK4A - Homozygous Deletion\nPRKAR1A - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic Neuroendocrine Tumor\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Everolimus\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": \"GNAS amplification, CDKN2A/B homozygous deletions, MEN1 mutation, DAXX mutation, PRKAR1A amplification\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204324s012lbl.pdf\"\n  }\n}"
}